Literature DB >> 21328434

Evaluation of empiric versus nomogram-based direct thrombin inhibitor management in patients with suspected heparin-induced thrombocytopenia.

Tyree H Kiser1, Allison M Mann, Toby C Trujillo, Kathryn L Hassell.   

Abstract

The aim of this study was to evaluate a direct thrombin inhibitor (DTI) titration protocol in patients with suspected HIT. This observational study compared patients treated with argatroban or bivalirudin according to the University of Colorado Hospital DTI titration protocol versus a control group treated prior to protocol implementation. Protocol patients had DTI initial doses based on organ function and fixed dosage adjustments of 10, 25, or 50%. Initial doses and titrations in the control group were made per physician discretion. A total of 130 patients were enrolled: 47 in the protocol group and 83 in the control group (median age 54 years, 63% male, 78% critically ill, and 54% received argatroban). Goal aPTT was achieved with initial DTI dose in 64% of protocol patients and 46% of control patients (P = 0.07). Median (IQR) time to goal aPTT was reduced in the protocol group compared to the control group [5 hr (2-10 hr) vs. 13 hr (6-29 hr); P < 0.0001]. Median time to dose stabilization was 10 hr (6-27 hr) and 22 hr (13-40 hr) in the protocol and control groups, respectively; P < 0.0001. Median number of titrations to goal was 0 (0-1) versus 1 (0-4), respectively; P = 0.02. Median percentage of aPTT values in goal was 67% (41-100%) versus 53% (33-76%), respectively; P = 0.027. The DTI titration protocol shortened time to achieve goal aPTT, reduced time to dose stabilization, decreased the number of titrations required to achieve aPTT goal, and improved the percentage of aPTT values in goal range.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21328434     DOI: 10.1002/ajh.21955

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  6 in total

1.  Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.

Authors:  Jacob T Beyer; Stuart E Lind; Sheila Fisher; Toby C Trujillo; Michael F Wempe; Tyree H Kiser
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

2.  Predicting and evaluating the effect of bivalirudin in cardiac surgical patients.

Authors:  Qi Zhao; Thomas Edrich; Ioannis Ch Paschalidis
Journal:  IEEE Trans Biomed Eng       Date:  2014-02       Impact factor: 4.538

Review 3.  Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis.

Authors:  Zhengwu Sun; Xiaoyan Lan; Shen Li; Hongling Zhao; Zeyao Tang; Yalin Xi
Journal:  Int J Hematol       Date:  2017-06-09       Impact factor: 2.490

4.  Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis.

Authors:  Se-Chan Kim; Nicole Tran; Jens-Christian Schewe; Olaf Boehm; Maria Wittmann; Ingo Graeff; Andreas Hoeft; Georg Baumgarten
Journal:  J Cardiothorac Surg       Date:  2015-02-07       Impact factor: 1.637

Review 5.  Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis.

Authors:  Giorgia Colarossi; Nicola Maffulli; Andromahi Trivellas; Heike Schnöring; Nima Hatam; Markus Tingart; Filippo Migliorini
Journal:  Int J Clin Pharm       Date:  2021-03-28

6.  Prophylaxis and treatment of venous thromboembolism in the critically ill.

Authors:  Sarah M Adriance; Claire V Murphy
Journal:  Int J Crit Illn Inj Sci       Date:  2013-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.